30.13
2.87%
+0.84
After Hours:
30.13
Omnicell, Inc. stock is currently priced at $30.13, with a 24-hour trading volume of 863.39K.
It has seen a +2.87% increased in the last 24 hours and a +9.29% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $28.61 pivot point. If it approaches the $30.32 resistance level, significant changes may occur.
Previous Close:
$29.29
Open:
$29.87
24h Volume:
863.39K
Market Cap:
$1.38B
Revenue:
$1.15B
Net Income/Loss:
$-20.37M
P/E Ratio:
-39.13
EPS:
-0.77
Net Cash Flow:
$126.08M
1W Performance:
+8.15%
1M Performance:
+9.29%
6M Performance:
-1.02%
1Y Performance:
-54.99%
Omnicell, Inc. Stock (OMCL) Company Profile
Name
Omnicell, Inc.
Sector
Industry
Phone
650-251-6100
Address
590 East Middlefield Road, Mountain View
Omnicell, Inc. Stock (OMCL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-03-24 | Initiated | Barclays | Underweight |
Nov-03-23 | Downgrade | BTIG Research | Buy → Neutral |
Nov-03-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Nov-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Oct-11-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Sep-26-23 | Reiterated | Wells Fargo | Underweight |
Aug-02-23 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-20-23 | Downgrade | Wells Fargo | Overweight → Underweight |
Feb-27-23 | Upgrade | The Benchmark Company | Hold → Buy |
Nov-03-22 | Downgrade | The Benchmark Company | Buy → Hold |
Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
Sep-09-22 | Initiated | BofA Securities | Buy |
Jul-15-22 | Initiated | SVB Leerink | Mkt Perform |
Dec-06-21 | Resumed | Wells Fargo | Overweight |
Jun-09-21 | Initiated | JP Morgan | Neutral |
May-24-21 | Initiated | BTIG Research | Buy |
Feb-02-21 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-08-20 | Initiated | Berenberg | Buy |
Dec-03-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jul-07-20 | Initiated | Stephens | Overweight |
Feb-07-20 | Reiterated | Dougherty & Company | Buy |
Nov-21-19 | Reiterated | Dougherty & Company | Buy |
Jul-26-19 | Upgrade | Craig Hallum | Hold → Buy |
Mar-07-19 | Reiterated | Dougherty & Company | Buy |
Jun-29-18 | Resumed | The Benchmark Company | Buy |
Sep-05-17 | Reiterated | The Benchmark Company | Buy |
Jul-28-17 | Reiterated | Dougherty & Company | Buy |
Apr-21-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
Jan-19-17 | Initiated | Dougherty & Company | Buy |
Dec-06-16 | Reiterated | The Benchmark Company | Buy |
Jul-07-16 | Reiterated | FBR Capital | Outperform |
Mar-21-16 | Reiterated | Topeka Capital Markets | Buy |
Jan-07-16 | Initiated | The Benchmark Company | Buy |
Nov-16-15 | Reiterated | Topeka Capital Markets | Buy |
Oct-30-15 | Reiterated | FBR Capital | Outperform |
Sep-28-15 | Upgrade | Sidoti | Neutral → Buy |
Jul-31-15 | Reiterated | Topeka Capital Markets | Buy |
View All
Omnicell, Inc. Stock (OMCL) Latest News
Omnicell (OMCL) Q1 Earnings and Revenues Top Estimates
Zacks Investment Research
GE HealthCare Technologies (GEHC) Meets Q1 Earnings Estimates
Zacks Investment Research
Here's Why You Should Retain Omnicell (OMCL) Stock Now
Zacks Investment Research
Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down
Zacks Investment Research
Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates
Zacks Investment Research
Here's Why You Should Retain Omnicell (OMCL) Stock Now
Zacks Investment Research
Omnicell, Inc. Stock (OMCL) Financials Data
Omnicell, Inc. (OMCL) Revenue 2024
OMCL reported a revenue (TTM) of $1.15 billion for the quarter ending December 31, 2023, a -11.48% decline year-over-year.
Omnicell, Inc. (OMCL) Net Income 2024
OMCL net income (TTM) was -$20.37 million for the quarter ending December 31, 2023, a -460.68% decrease year-over-year.
Omnicell, Inc. (OMCL) Cash Flow 2024
OMCL recorded a free cash flow (TTM) of $126.08 million for the quarter ending December 31, 2023, a +639.85% increase year-over-year.
Omnicell, Inc. (OMCL) Earnings per Share 2024
OMCL earnings per share (TTM) was -$0.45 for the quarter ending December 31, 2023, a -550.00% decline year-over-year.
About Omnicell, Inc.
Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Cap:
|
Volume (24h):